Affinia Therapeutics Receives FDA Clearance to Begin Phase 1/2 Trial of AFTX-201 Gene Therapy for Rare Heart Disease
核心洞察
The FDA has accepted Affinia Therapeutics (搜索)' IND application for AFTX-201, a gene therapy targeting BAG3-associated dilated cardiomyopathy (搜索), clearing the path for clinical trials.
AFTX-201 utilizes a proprietary capsid technology that enables cardiac transduction at doses 5-10-fold lower than conventional gene therapy capsids.
The multicenter UPBEAT Phase 1/2 trial will evaluate safety and preliminary efficacy in adults with genetically confirmed BAG3 (搜索) DCM, with initiation planned for the first half of 2026.
Affinia Therapeutics (搜索) announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug application for AFTX-201, an investigational gene therapy for BAG3-associated dilated cardiomyopathy (搜索) (DCM). The regulatory milestone clears the way for the company to initiate the UPBEAT clinical trial in the first half of 2026, representing a significant step forward for patients with this devastating inherited heart condition.
Novel Gene Therapy Approach
AFTX-201 is designed to deliver a fully human, full-length functional BAG3 (搜索) transgene using Affinia's proprietary capsid engineered for efficient cardiac transduction. The therapy's key advantage lies in its ability to achieve therapeutic effects at doses that are 5-10-fold lower than those associated with gene therapy products using conventional capsids such as AAV9 or AAVrh74. The treatment is intended to be administered as a simple one-time intravenous infusion.
Preclinical studies in an animal disease model demonstrated promising results, with AFTX-201 increasing BAG3 (搜索) protein levels in the heart and completely restoring cardiac function. The nonclinical studies showed complete correction of heart ejection fraction to normal (wild type) levels and provided an adequate safety margin for the doses being explored in the clinical trial.
UPBEAT Clinical Trial Design
The UPBEAT clinical trial is a multicenter, single-arm open-label Phase 1/2 study designed to evaluate the safety, tolerability, pharmacodynamics, and preliminary efficacy of AFTX-201 in adults with genetically confirmed BAG3-associated dilated cardiomyopathy (搜索). The trial structure includes a dose-exploration phase followed by a dose-expansion phase.
All participants will receive a single intravenous infusion of AFTX-201 at a dose determined to be safe and efficacious based on preclinical studies. The primary objective focuses on evaluating safety and tolerability through 52 weeks following administration, while secondary and exploratory objectives include pharmacodynamic and preliminary efficacy assessments measured as changes from baseline.
The study incorporates robust safety measures, including protocol-defined stopping rules, centralized safety data review, and oversight by an independent Data Safety Monitoring Board. The trial design, dose selection, and monitoring plans were informed by input from patients, clinicians, and regulators.
Addressing Significant Unmet Medical Need
BAG3 (搜索) dilated cardiomyopathy (搜索) represents a serious inherited heart condition with high mortality rates and significant unmet medical needs. The disease affects more than 70,000 patients across Canada, the European Union, United States, and United Kingdom. The BAG3 gene encodes for a protein critical to the normal structure and function of heart cells.
Patients with BAG3 (搜索) DCM carry mutations in the BAG3 gene and experience deficiency in functional BAG3 protein, resulting in early onset heart failure (搜索) that progresses rapidly. Despite current standard of care treatments, almost 25% of patients require heart transplants, highlighting the urgent need for effective therapeutic interventions.
"BAG3 (搜索) DCM is a genetic heart disease with significant medical need despite current standard of care," said Matthew Wheeler, M.D., Ph.D., a physician scientist in genetic cardiomyopathies and Associate Professor in Cardiovascular Medicine at Stanford Medicine. "A gene therapy approach could make a real difference to patients living with BAG3 DCM."
Clinical Development Timeline
Hideo Makimura, M.D., Ph.D., Chief Medical Officer at Affinia, expressed gratitude for the FDA's timely review and the support from the patient and clinician community. "We look forward to initiating the UPBEAT clinical trial at multiple trial sites in the coming weeks and bringing a much-needed treatment option for patients and families affected by this devastating disease," Makimura stated.
The company is positioned to begin patient enrollment in the multicenter trial, with interested participants encouraged to reach out through their clinical trials contact system. The advancement of AFTX-201 represents Affinia Therapeutics (搜索)' broader mission to develop first-in-class and best-in-class adeno-associated virus gene therapies for devastating cardiovascular diseases.